Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation

Biochemical Pharmacology

Volumn 61, Issue 3, 2001, Pages 373-379

  Sobal, Grazyna ^a   Menzel, Ernst Johannes ^a   Sinzinger, Helmut ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Calcium antagonists; Diabetes mellitus; Glycation; Glycoxidation; Low density lipoprotein

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMLODIPINE; ANTIOXIDANT; CALCIUM ANTAGONIST; DILTIAZEM; ISRADIPINE; LACIDIPINE; NIFEDIPINE; OXIDIZED LOW DENSITY LIPOPROTEIN; SESAMODIL FUMARATE;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; GLYCATION; HUMAN; LIPID PEROXIDATION; PRIORITY JOURNAL;

ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 0035253838     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00548-7     Document Type: Article

References (43)

1. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
2. LDL undergoes oxidative modificationin vivo
3. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man
4. Autoantibody against oxidised LDL and progression of carotid atherosclerosis
5. Autoantibodies to oxidized LDL: The relationship to LDL fatty acid composition in diabetes
6. Autoantibodies to oxidised low-density lipoproteins in IDDM are inversely correlated with severity of disease
7. Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endotheliumin vivo
8. Effects of native and oxidized LDL on formation and inactivation of endothelium-derived relaxing factor
9. Oxidized low-density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide
10. Oxidized LDL increases human endothelial cell tissue factor activity and reduces protein C activation
11. Diabetes and atherosclerosis: An epidemiologic view
12. Role of diabetes in cardiac disease: Conclusions from population studies: The Framingham Study
13. 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and non-diabetic subjects
14. Pathophysiological concentrations of glucose promote oxidative modification of LDL by a superoxide-dependent pathway
15. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose
16. Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes
17. Catalysis of lipid peroxidation by glucose and glycosylated collagen
18. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo
19. The role of oxidative stress in the long-term glycation of LDL
20. Glycosylated LDL is more sensitive to oxidation: Implications for the diabetic patients?
21. Modification of LDL by advanced glycation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency
22. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM
23. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity
24. Calcium-channel blockers inhibit low-density lipoprotein oxidation by oxygen radicals
25. 2+-channel and α1-adrenoreceptor antagonist monatepil maleate
26. Impact of a combination of calcium antagonist and a beta-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells
27. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol
28. Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein
29. The binding of two dihydropyridines to isolated and native plasma lipoproteins
30. Effects of calcium antagonists on oxidative susceptibility of low density lipoprotein (LDL)
31. LDL oxidation: Therapeutic perspectives
32. Differential expression of receptors for AGEs on monocytes from patients with IDDM
33. Microsomal lipid peroxidation
34. Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem
35. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients
36. Calcium channel blockers with antioxidant activity
37. Comparative effect of ursodeoxycholic acid and calcium antagonists on the binding, uptake and degradation of LDL in isolated hamster hepatocytes
38. Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL oxidation
39. 2 and analogues (taprostene, iloprost) on oxidation of native and glycated low density lipoprotein
40. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): Amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins
41. Simulation of the induction of oxidation of low-density lipoprotein by high copper concentrations: Evidence for a nonconstant rate of initiation
42. Glycation, glycoxidation, and cross-linking of collagen by glucose
43. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes